Director John Jette Campbell receives 2,013 KEQU shares as annual equity award

Rhea-AI Filing Summary

Campbell John Jette reported acquisition or exercise transactions in this Form 4 filing.

Kewaunee Scientific director John Jette Campbell received an equity grant of 2,013 shares of Common Stock as part of his annual compensation. The shares were awarded at no cash cost under the company’s 2023 Omnibus Incentive Plan, increasing his directly held position to 2,703 shares after the award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Campbell John Jette

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,013	$0.00	--

Holdings After Transaction: Common Stock — 2,703 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant: 2,013 shares Holdings after grant: 2,703 shares Grant price per share: $0.0000

3 metrics

Equity grant 2,013 shares Common Stock award as annual compensation

Holdings after grant 2,703 shares Total Common Stock directly held after transaction

Grant price per share $0.0000 Compensation grant, no cash purchase price

Key Terms

Omnibus Incentive Plan, annual compensation, Common Stock

3 terms

Omnibus Incentive Plan financial

"Shares awarded under the Company's 2023 Omnibus Incentive Plan"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

annual compensation financial

"representing the equity portion of the reporting person's annual compensation"

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell John Jette

(Last) (First) (Middle)

2700 WEST FRONT STREET

(Street)

STATESVILLE NORTH CAROLINA 28677

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		A		2,013	A	$0(1)	2,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares awarded under the Company's 2023 Omnibus Incentive Plan, representing the equity portion of the reporting person's annual compensation.

Remarks:

	/s/ Donald T. Gardner III, Attorney-in-fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kewaunee Scientific (KEQU) director John Jette Campbell report on this Form 4?

He reported receiving 2,013 shares of Kewaunee Scientific Common Stock as an equity grant. The award represents the equity portion of his annual compensation and was made under the company’s 2023 Omnibus Incentive Plan at no cash purchase price.

How many Kewaunee Scientific (KEQU) shares does John Jette Campbell hold after this transaction?

Following the equity grant, John Jette Campbell directly holds 2,703 shares of Kewaunee Scientific Common Stock. This post-transaction total reflects the addition of 2,013 awarded shares to his existing holdings, as disclosed in the Form 4 filing’s ownership table.

Was the Kewaunee Scientific (KEQU) Form 4 transaction a market purchase or a compensation grant?

The transaction was a compensation-related grant, not a market purchase. The Form 4 uses code “A” for a grant or award, and the footnote explains the 2,013 shares were issued as the equity portion of Campbell’s annual compensation under the 2023 Omnibus Incentive Plan.

Did John Jette Campbell pay a price per share for the 2,013 Kewaunee Scientific (KEQU) shares?

No cash price was paid for the shares. The Form 4 lists the transaction price per share as 0.0000, indicating the 2,013 Common Stock shares were granted as compensation rather than purchased in the market for cash consideration.

What plan governed the equity award reported by Kewaunee Scientific (KEQU) director John Jette Campbell?

The equity award was made under Kewaunee Scientific’s 2023 Omnibus Incentive Plan. The Form 4 footnote states the 2,013 shares represent the equity portion of Campbell’s annual compensation granted pursuant to this incentive plan framework.